As a new-type foreign trade service provider driven by both technology commercialization and foreign trade, HiSiaddi has established a service system summarized as “1+2+3+4=1” and can supply dibenzyl ether sourced from multiple well-known original manufacturers. Possessing R&D capabilities, HiSiaddi has repeatedly resolved customized dibenzyl ether product demands for clients through technological cooperation with manufacturers and precise insight into market demands. Below is a case demonstrating how HiSiaddi delivered a customized dibenzyl ether solution.
Contact HiSiaddi customer service for more customized service inquiries.
BIOPHARMA AG, headquartered in Geneva, Switzerland, is a listed high-tech pharmaceutical enterprise specializing in targeted API R&D and formulation manufacturing. With 28 years of experience in high-end antibiotics and peptide new drug synthesis, it supplies APIs to multiple cross-border pharmaceutical groups and EU public pharmaceutical research institutes across Europe. Dibenzyl ether is used as a high-purity solvent dedicated to hydroxyl protection in pharmaceutical synthesis for its new generation cephalosporin derivative APIs. The enterprise previously purchased original pharmaceutical-grade dibenzyl ether from LANXESS of Germany on a long-term basis with an annual stable order volume of 120 tons. Its products comply with the European Pharmacopoeia (EP), ICH impurity control standards, REACH regulation and EDMF API filing requirements, making it a high-end client with extremely stringent limits on impurities, distillation range and trace by-products.
Due to overhaul of local European chemical facilities, continuous surges in imported raw material prices and extended overseas delivery lead times exceeding 60 days, the client launched a localization substitution program for customized products. Conventional industrial-grade domestic dibenzyl ether failed to meet the synthesis requirements of its new drugs, requiring non-standard customized pharmaceutical-grade dibenzyl ether. After independently contacting 5 domestic dibenzyl ether manufacturers, the client received rejections from all: all factories only mass-produced standard 98.5% industrial-grade products without customized R&D capacity. Their existing processes could not remove benzyl alcohol, benzyl chloride and peroxide impurities restricted by the client, halting the pilot mass production of the client’s new drugs. The client therefore fully entrusted HiSiaddi to oversee customized product development, pilot sampling and industrial mass production implementation.
1. Purity ≥99.85% (ordinary domestic industrial products only reach 98%~98.5%, requiring deep rectification and purification);
2. Single impurity control limits: residual benzyl alcohol ≤100ppm, benzyl chloride ≤20ppm, peroxides <5ppm; conventional domestic processes result in by-products 10 to 30 times above these limits;
3. Color APHA ≤10, colorless with no faint yellow tint; trace aromatic impurities must be eliminated to avoid adverse impacts on color difference and efficacy stability of finished APIs;
4. Narrow full distillation range control (296~299°C); ordinary industrial products have a distillation range span over 8°C, which easily triggers side reactions during the client’s synthetic process and causes API scrapping;
5. Supporting documentation: full impurity chromatograms compliant with European EDMF filing, process validation reports, stability test data for three consecutive batches, English Certificates of Analysis (CoA), and pharmaceutical-grade Safety Data Sheets (SDS).
1. Manufacturers were reluctant to modify production processes: most domestic dibenzyl ether producers manufacture general industrial-grade products by rectifying benzyl alcohol by-products with fixed production lines. Revamping rectification towers and installing fine impurity removal units incurs high costs, and single factories refused to adjust production equipment solely for niche high-end customization orders;
2. Lack of impurity R&D capabilities: regular manufacturers only conduct routine national standard testing without laboratories for full chromatographic impurity screening, making targeted removal of peroxides and trace halogen impurities impossible;
3. Disconnection between lab trials and pilot production: factories only engage in bulk mass production and refused to supply gradient small-batch samples of 5kg and 25kg required by the client’s R&D for formula verification;
4. Absence of pharmaceutical compliance supporting documents: domestic manufacturers could not issue EP Pharmacopoeia-aligned test reports or process dossiers required for EDMF filing, failing to pass the pharmaceutical supply chain audit standards of the Swiss pharmaceutical enterprise.
Leveraging its refined ether industrial chain resources, HiSiaddi screened 2 domestic chemical plants equipped with continuous rectification facilities and supporting pharmaceutical-grade quality inspection laboratories. Exclusive customized dedicated production lines were negotiated and revamped, with independent small-scale rectification production lines allocated by the factories. Reaction sections, three-stage precision vacuum rectification towers and peroxide removal adsorption refining units were renovated separately to avoid cross-contamination from general mass production pipelines.
1. Lab-scale trial (5kg samples): Raw material feeding ratios and phase transfer catalyst types were adjusted, alongside temperature-controlled reaction processes to mitigate excessive by-products generated by traditional alkali catalysis. A molecular sieve adsorption unit was added to eliminate trace benzyl alcohol impurities, and anti-oxidation light-shielded rectification was adopted to inhibit peroxide formation. HiSiaddi simultaneously engaged a third-party authoritative pharmaceutical testing laboratory to conduct full-spectrum chromatographic testing in accordance with EP Pharmacopoeia standards. Partial impurities in the first batch of samples still exceeded specified limits.
2. Secondary process fine-tuning (25kg pilot samples): Vacuum rectification segmented temperature control parameters were optimized with segmented distillate cutting to remove high and low boiling point impurity fractions, and anti-oxidation stabilizers were replaced. After secondary testing, all key impurities met the specified limits, purity reached 99.89%, and color APHA hit 8—all indicators surpassed the client’s upper customization thresholds.
3. 500kg industrial trial production: A finalized production process was locked in, with fixed raw material sources, reaction temperatures and rectification pressure parameters, and standardized SOP production documents established. Full re-testing of trial batches delivered stable data with inter-batch indicator fluctuations below 0.05%, satisfying the client’s requirements for continuous production stability.
Cooperating with the R&D and quality inspection departments of the manufacturing plant, HiSiaddi organized a full set of customized process documents:
1. Compile full impurity HPLC/GC chromatograms, process development reports and three batches of accelerated stability investigation reports;
2. Issue Chinese-English bilingual Certificates of Analysis aligned with the European Pharmacopoeia, complete the 16-item GHS pharmaceutical-grade SDS, assist the client in filing EDMF documentation, and successfully pass the on-site pharmaceutical compliance QA audit by the client’s headquarters.
In compliance with the clean storage requirements of the Swiss pharmaceutical enterprise, 200L iron drums with food-grade internal stainless steel lining were customized, printed with German-English bilingual CLP compliance labels distinct from industrial packaging specifications. Monthly production batches were split according to the client’s monthly consumption plan to avoid capacity occupation by general products during factory peak seasons.
1. Successful sample delivery & mass production launch: After receiving three gradient batches of samples and completing three rounds of API synthesis pilot trials, the customized dibenzyl ether fully matched the client’s new drug synthesis process. Side reactions decreased by 90%, and the yield of qualified APIs rose from 97.2% with the original imported material to 99.5%. The first 60-ton mass production shipment cleared customs and entered warehouses in Switzerland without issues.
2. Optimized procurement costs: The overall comprehensive procurement cost of domestically customized pharmaceutical-grade dibenzyl ether dropped by 29% compared to original LANXESS imports, cutting annual raw material procurement expenses by over 146,000 Euros.
3. Long-term framework cooperation: The client signed an annual fixed-price framework contract for 120 tons, and entrusted HiSiaddi with advance customized development of modified substituted dibenzyl ether derivatives required for two pipeline new drugs under its portfolio.
4. Extended supply chain coverage: Supported by the full EP-grade production process and compliance dossiers, the client introduced this customized dibenzyl ether to API production lines of its subsidiaries in France and Italy simultaneously.
1. Domestic dibenzyl ether manufacturers mainly mass-produce general industrial-grade by-product materials with fixed production lines, focusing on high-volume bulk orders while lacking willingness and supporting R&D capabilities for high-end pharmaceutical non-standard customization—this constitutes the biggest pain point for overseas high-end pharmaceutical enterprises seeking domestic customized substitution.
2. Core Value of HiSiaddi: Connecting end-user customized indicators, factory process technical transformation, third-party pharmacopoeia testing and EU pharmaceutical compliance across the full industrial chain, acting as a technical bridge between high-end clients and manufacturers to deliver niche high-end non-standard customized solutions.
3. Core procurement demands of European and American high-end pharmaceutical enterprises extend far beyond low unit prices: targeted impurity control, traceable processes, pharmacopoeia compliance and batch consistency are the core factors securing long-term customized cooperation.
Contact HiSiaddi customer service for more customized service inquiries.
+86-13120989737 
info@hisiaddi.com 
English
